RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BIAGIOLI E
Collezione AOU Città della Salute di Torino

Items : 2

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2.

2024
AO Ordine Mauriziano
AOU Città della Salute di Torino

Barretina Ginesta MP; Uggeri S; Rulli E; Laudani ME; Lissoni AA; Petrella M; Tognon G; Ferrero A; Manso L; Takehara K; Tasca G; Zamagni C; McQueen J; Nakagawa S; Piovano E; Pardo B; Lee YC; Nishio S; Allan K; Fariñas-Madrid L; Parma G; Marth C; Marmé F; Rabaglio M; Antill Y; Choi CH; Hudson E; Galli F; Harano K; et alii...

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. in British journal of cancer / Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9.

2023
AOU Città della Salute di Torino
ASL Vercelli

Aglietta M; Arcangeli V; Benedetti Panici P; De Giorgi U; Zola P; Rubio-Pérez MJ; DeCensi A; Tognon G; Pardo B; Romeo M; Tasca G; Funari G; Iglesias M; Biagioli E; Mirza MR; Deryal M; Fossati R; Barretina-Ginesta MP; Herbertson R; Riniker S; Nyvang GB; Chekerov R; Churruca Galaz C; D'Incalci M; Vergote I; Berger R; Ottevanger NB; Montes A; Sessa C; et alii...